Alpine Immune Sciences, Inc. (ALPN) financial statements (2020 and earlier)

Company profile

Business Address 188 EAST BLAINE ST., SUITE 200
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41475664526270
Cash and cash equivalents1617154111114
Short-term investments24294023425166
Restricted cash and investments00     
Receivables00  0  
Prepaid expense01  0  
Deferred costs0   000
Other undisclosed current assets1521012
Total current assets:42525765546372
Noncurrent Assets
Operating lease, right-of-use asset101111 
Property, plant and equipment2111111
Restricted cash and investments0000000
Other undisclosed noncurrent assets   1   
Total noncurrent assets:1212132111
TOTAL ASSETS:54657067556573
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities71286651
Accounts payable2621201
Accrued liabilities5665441
Deferred revenue122 
Debt0 32222
Deferred rent credit    0  
Deferred revenue and credits00
Other undisclosed current liabilities   1   
Total current liabilities:914139873
Noncurrent Liabilities
Long-term debt and lease obligation1616122233
Long-term debt, excluding current maturities5512233
Operating lease, liability111111 
Liabilities, other than long-term debt     00
Deferred revenue and credits00
Total noncurrent liabilities:1616122233
Total liabilities:2530251110107
Stockholders' equity
Stockholders' equity attributable to parent, including:29354557455567
Additional paid in capital117117116115919089
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(88)(82)(70)(58)(46)(35)(23)
Other undisclosed stockholders' equity attributable to parent0000000
Total stockholders' equity:29354557455567
TOTAL LIABILITIES AND EQUITY:54657067556573

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenue, net0
Gross profit:101   0
Operating expenses(8)(12)(13)(13)(11)(12)(9)
Operating loss:(7)(12)(12)(13)(11)(12)(8)
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes2      
Loss from continuing operations before equity method investments, income taxes:(5)(12)(12)(13)(12)(12)(8)
Other undisclosed income (loss) from continuing operations before income taxes(1)000000
Loss from continuing operations before income taxes:(6)(11)(12)(12)(11)(12)(8)
Income tax benefit    0 0
Net loss available to common stockholders, diluted:(6)(11)(12)(12)(11)(12)(8)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(6)(11)(12)(12)(11)(12)(8)
Comprehensive loss:(6)(11)(12)(12)(11)(12)(8)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)00000
Comprehensive loss, net of tax, attributable to parent:(6)(11)(12)(12)(11)(12)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: